Description General description A cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC50 = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE2 and COX-2 in human monocytes and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model. A cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF tautomerase activity by binding to its catalytic active site (IC50 = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE2 and COX-2 in human monocytes, and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model. Also available as a 50 mM solution in DMSO (Cat. No. 505225). Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target MIF tautomerize Product does not compete with ATP. Reversible: no Target IC50: 7 µM for D-dopachrome tautomerase Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstituion, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Cvetkovic, I., et al. 2005. Endocrinology, 146, 2942. Lubetsky, J.B., et al. 2002. J. Biol. Chem.277, 24976.